Risankizumab

Trade Name: 
Skyrizi
Manufacturer/Distributor: 
AbbVie Corporation
Classification: 
Interleukin-23 inihbitor
ATC Class: 
L04AC - interleukin inhibitors
Status: 
active
Notice of Compliance (yyyy/mm/dd): 
2019/04/13
Date Marketed in Canada (yyyy/mm/dd): 
2019/05/13
Presentation: 
Injection: 90 mg/mL. DIN: 02487454
Comments: 
For treatment of adults with moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy.
Source: 
Product monograph